Key result
A concentration of more than 0.1 mg (10 Toronto units) of heparin per cc of human blood is required to prevent clumping of platelets in vitro.
Population
Human blood in vitro (and rabbit model)
Design
Preclinical
Authors
Loading...
Does not support clinical heparin dosing changes; leaves open in vivo validation of the platelet inhibition threshold.
In vitro experiments demonstrate that a concentration of >0.1 mg/cc of heparin is required to prevent platelet agglutination in human blood.
Baronofsky et al. (1943) studied this question. Heparin was evaluated on Prevention of platelet agglutination in vitro. A concentration of more than 0.1 mg (10 Toronto units) of heparin per cc of human blood is required to prevent clumping of platelets in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: